LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 132

Search options

  1. Book: Novel therapies for relapsed, refractory multiple myeloma

    Jakubowiak, Andrzej J.

    how can we improve on "salvage" therapy?

    (Seminars in hematology ; 49,3, Suppl. 1)

    2012  

    Author's details Andrzej Jakubowiak, guest ed
    Series title Seminars in hematology ; 49,3, Suppl. 1
    Collection
    Language English
    Size A3, S46 S. : graph. Darst.
    Publisher Saunders
    Publishing place Philadelphia, PA
    Publishing country United States
    Document type Book
    HBZ-ID HT017334248
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 328 -49,Suppl.1- not available for loan Zeitschriften-Lesesaal

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Book: Emerging treatment options for relapsed and refractory multiple myeloma

    Siegel, David S. / Vij, Ravi / Jakubowiak, Andrzej J.

    (Clinical advances in hematology & oncology ; 9,4, Suppl. 6 : Clinical roundtable monograph)

    2011  

    Author's details moderator David S. Siegel. Discussants Ravi Vij ; Andrzej J. Jakubowiak
    Series title Clinical advances in hematology & oncology ; 9,4, Suppl. 6 : Clinical roundtable monograph
    Collection
    Language English
    Size 15 S. : Ill.
    Publisher Millennium Med. Publ
    Publishing place New York, NY
    Publishing country United States
    Document type Book
    HBZ-ID HT017150559
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 6505 -9,Suppl.6- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma.

    Derman, Benjamin A / Jakubowiak, Andrzej J / Thompson, Michael A

    Blood cancer journal

    2022  Volume 12, Issue 7, Page(s) 108

    MeSH term(s) Humans ; Multiple Myeloma/drug therapy ; Neoplasm, Residual ; Surveys and Questionnaires
    Language English
    Publishing date 2022-07-11
    Publishing country United States
    Document type Letter
    ZDB-ID 2600560-8
    ISSN 2044-5385 ; 2044-5385
    ISSN (online) 2044-5385
    ISSN 2044-5385
    DOI 10.1038/s41408-022-00705-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Measurable residual disease in peripheral blood in myeloma: dream or reality.

    Kubicki, Tadeusz / Derman, Benjamin A / Dytfeld, Dominik / Jakubowiak, Andrzej J

    Current opinion in oncology

    2023  Volume 35, Issue 6, Page(s) 574–580

    Abstract: Purpose of review: Therapeutic advancements in multiple myeloma have led to increasingly deeper and more durable responses, creating a need for highly sensitive and applicable techniques for measurable residual disease (MRD) assessment. Bone marrow ... ...

    Abstract Purpose of review: Therapeutic advancements in multiple myeloma have led to increasingly deeper and more durable responses, creating a need for highly sensitive and applicable techniques for measurable residual disease (MRD) assessment. Bone marrow assays can deeply assess for MRD, but it is not conducive to performing frequent and dynamic evaluations, which may be needed for MRD-adapted treatment approaches. Recently, numerous techniques for MRD assessment in peripheral blood have come under investigation, and their integration into routine clinical practice is eagerly anticipated.
    Recent findings: The identification of circulating tumor cells (CTCs), evaluation of cell-free DNA, and measuring monoclonal protein concentration with mass spectrometry are promising research areas for assessing myeloma in peripheral blood. CTCs assessment and cell-free DNA may carry prognostic significance, but they lack the sensitivity of bone marrow-based techniques. Mass spectrometry has already been implemented in clinical practice in certain centers, but its full potential has yet to be fully realized. This review focuses on recent developments in these fields, emphasizing the potential future roles of these assessments.
    Summary: MRD assessment in peripheral blood is still in the development stage but holds promise for not only complementing bone marrow based evaluations but also potential for improving sensitivity.
    Language English
    Publishing date 2023-08-13
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1049384-0
    ISSN 1531-703X ; 1040-8746
    ISSN (online) 1531-703X
    ISSN 1040-8746
    DOI 10.1097/CCO.0000000000000987
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3046: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma.

    Major, Ajay / Jakubowiak, Andrzej / Derman, Benjamin

    Clinical lymphoma, myeloma & leukemia

    2022  Volume 22, Issue 11, Page(s) e1000–e1008

    Abstract: Background: Peripheral neuropathy is a common treatment-emergent side effect during the treatment of newly diagnosed multiple myeloma. Although bortezomib is most commonly implicated, real-world data suggest that lenalidomide and dexamethasone (VRd) and ...

    Abstract Background: Peripheral neuropathy is a common treatment-emergent side effect during the treatment of newly diagnosed multiple myeloma. Although bortezomib is most commonly implicated, real-world data suggest that lenalidomide and dexamethasone (VRd) and autologous stem cell transplantation (ASCT) may also contribute to neuropathy and health-related quality of life (HRQoL).
    Methods: The Multiple Myeloma Research Foundation (MMRF) CoMMpass Registry was queried for all patients who received frontline VRd or bortezomib, cyclophosphamide and dexamethasone (VCd). Incidence of neuropathy and patient-reported HRQoL outcomes over the first 12 months after diagnosis were compared between patients receiving VRd or VCd with or without early ASCT before 6 months.
    Results: There were 368 and 191 patients treated with VRd and VCd, respectively. VRd with early ASCT was associated with worse grade 1 neuropathy compared to VRd without early ASCT, as well as compared to VCd with early ASCT. There were no differences in neuropathy between VRd and VCd without early ASCT, and no differences in grade ≥2 neuropathy. There were significant improvements in HRQoL between baseline and 12 months in both VRd and VCd cohorts, regardless of early ASCT. Development of neuropathy was not associated with decrements in progression-free survival or overall survival.
    Conclusions: In this longitudinal database analysis, there were no differences in grade ≥2 neuropathy between VRd and VCd frontline induction, and overall HRQoL significantly improved across all cohorts. However, differences in grade 1 neuropathy between VRd and VCd induction suggest that lenalidomide and high-dose melphalan may augment the risk of neuropathy in newly diagnosed multiple myeloma.
    MeSH term(s) Humans ; Lenalidomide/therapeutic use ; Bortezomib/adverse effects ; Multiple Myeloma/diagnosis ; Multiple Myeloma/drug therapy ; Melphalan/therapeutic use ; Hematopoietic Stem Cell Transplantation ; Quality of Life ; Transplantation, Autologous ; Dexamethasone/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cyclophosphamide/therapeutic use ; Peripheral Nervous System Diseases/chemically induced ; Patient Reported Outcome Measures
    Chemical Substances Lenalidomide (F0P408N6V4) ; Bortezomib (69G8BD63PP) ; Melphalan (Q41OR9510P) ; Dexamethasone (7S5I7G3JQL) ; Cyclophosphamide (8N3DW7272P)
    Language English
    Publishing date 2022-07-11
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2540992-X
    ISSN 2152-2669 ; 2152-2650
    ISSN (online) 2152-2669
    ISSN 2152-2650
    DOI 10.1016/j.clml.2022.07.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5903: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Knowing the unknowns in high risk multiple myeloma.

    Derman, Benjamin A / Kosuri, Satyajit / Jakubowiak, Andrzej

    Blood reviews

    2021  Volume 51, Page(s) 100887

    Abstract: High risk multiple myeloma (HRMM) continues to portend worse outcomes despite the many advances in anti-myeloma therapeutics. The optimal approach to treatment is not clearly defined on account of the variable definitions of HRMM and the paucity of ... ...

    Abstract High risk multiple myeloma (HRMM) continues to portend worse outcomes despite the many advances in anti-myeloma therapeutics. The optimal approach to treatment is not clearly defined on account of the variable definitions of HRMM and the paucity of studies dedicated to the treatment of HRMM. In this review, we use a case-based approach to review the definitions of HRMM, and evaluate the evidence for induction, stem cell transplantation, and post-transplant therapy approaches for HRMM.
    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols ; Hematopoietic Stem Cell Transplantation ; Humans ; Multiple Myeloma/diagnosis ; Multiple Myeloma/etiology ; Multiple Myeloma/therapy ; Stem Cell Transplantation ; Transplantation, Autologous
    Language English
    Publishing date 2021-08-28
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 639015-8
    ISSN 1532-1681 ; 0268-960X
    ISSN (online) 1532-1681
    ISSN 0268-960X
    DOI 10.1016/j.blre.2021.100887
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2207: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Novel therapies for relapsed/refractory multiple myeloma: how can we improve on "salvage" therapy?--introduction.

    Jakubowiak, Andrzej

    Seminars in hematology

    2012  Volume 49 Suppl 1, Page(s) S1–2

    MeSH term(s) Humans ; Multiple Myeloma/drug therapy ; Recurrence ; Salvage Therapy/methods
    Language English
    Publishing date 2012-07
    Publishing country United States
    Document type Introductory Journal Article
    ZDB-ID 206923-4
    ISSN 1532-8686 ; 0037-1963
    ISSN (online) 1532-8686
    ISSN 0037-1963
    DOI 10.1053/j.seminhematol.2012.05.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 328: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Clinician attitudes and practices toward measurable residual disease in multiple myeloma.

    Derman, Benjamin A / Jasielec, Jagoda K / Jakubowiak, Andrzej J

    British journal of haematology

    2020  Volume 190, Issue 3, Page(s) 470–472

    MeSH term(s) Attitude of Health Personnel ; Bone Marrow Examination/methods ; Clinical Decision-Making ; Disease Progression ; Flow Cytometry ; Health Care Surveys ; Health Knowledge, Attitudes, Practice ; High-Throughput Nucleotide Sequencing ; Humans ; Multiple Myeloma/pathology ; Multiple Myeloma/psychology ; Multiple Myeloma/therapy ; Neoplasm, Residual/diagnosis ; Neoplasm, Residual/psychology ; Physicians/psychology ; Positron Emission Tomography Computed Tomography ; Practice Patterns, Physicians' ; Sensitivity and Specificity ; Surveys and Questionnaires ; Time Factors
    Language English
    Publishing date 2020-06-07
    Publishing country England
    Document type Letter ; Research Support, N.I.H., Extramural
    ZDB-ID 80077-6
    ISSN 1365-2141 ; 0007-1048
    ISSN (online) 1365-2141
    ISSN 0007-1048
    DOI 10.1111/bjh.16805
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.182: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives.

    Jakubowiak, Andrzej

    Seminars in hematology

    2012  Volume 49 Suppl 1, Page(s) S16–32

    Abstract: In the last decade, the introduction of novel agents including the immunomodulatory drugs thalidomide and lenalidomide, and the first-in-class proteasome inhibitor bortezomib, has dramatically improved clinical outcome in patients with relapsed/ ... ...

    Abstract In the last decade, the introduction of novel agents including the immunomodulatory drugs thalidomide and lenalidomide, and the first-in-class proteasome inhibitor bortezomib, has dramatically improved clinical outcome in patients with relapsed/refractory multiple myeloma (MM) compared to conventional chemotherapy alone. Although combination treatment approaches with traditional cytotoxic agents and novel agents have led to response rates as high as 85% in patients with relapsed/refractory disease, not all patients will respond to established novel agents, and even those who do respond will ultimately relapse or become refractory to currently available regimens. There is no generally accepted standard treatment for patients with relapsed/refractory disease; however, both disease-related (eg, quality and duration of response to previous therapies and the aggressiveness of the relapse) and patient-related (eg, preexisting toxicities, comorbid conditions, quality of life, age, and performance status) factors should be considered when selecting the best treatment option. This article will review up-to-date approaches for managing patients with relapsed/refractory MM, including the efficacy and safety of established novel agents, the use of adjunctive/supportive care, and strategies for tailored treatment.
    MeSH term(s) Antineoplastic Agents/therapeutic use ; Humans ; Multiple Myeloma/drug therapy ; Multiple Myeloma/therapy ; Recurrence
    Chemical Substances Antineoplastic Agents
    Language English
    Publishing date 2012-07
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 206923-4
    ISSN 1532-8686 ; 0037-1963
    ISSN (online) 1532-8686
    ISSN 0037-1963
    DOI 10.1053/j.seminhematol.2012.05.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 328: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.

    Jakubowiak, Andrzej J

    Cancer treatment reviews

    2014  Volume 40, Issue 6, Page(s) 781–790

    Abstract: Carfilzomib is a proteasome inhibitor that binds selectively and irreversibly to its target. In July 2012, carfilzomib received accelerated approval in the United States for the treatment of relapsed and refractory multiple myeloma. Based on emerging ... ...

    Abstract Carfilzomib is a proteasome inhibitor that binds selectively and irreversibly to its target. In July 2012, carfilzomib received accelerated approval in the United States for the treatment of relapsed and refractory multiple myeloma. Based on emerging preclinical data and clinical results, the total dose, infusion time, and administration schedule of carfilzomib have evolved during phase I and phase II clinical studies, with the aim of optimizing the risk-benefit profile of the agent. Based on in vitro and in vivo findings and encouraging phase I tolerability data, a consecutive-day, twice-weekly dosing schedule was implemented early in the development program. Other phase II studies have led to further refinements in the dosing schedule of carfilzomib, resulting in the current approved schedule for carfilzomib to be administered intravenously over 2-10 min on 2 consecutive days each week for 3 weeks of a 28-day cycle. Prolonged infusion over 30 min has also been assessed in clinical studies to enable the use of higher carfilzomib doses with the aim of improving drug tolerability and efficacy. These data collectively informed the dosing and scheduling schemas for carfilzomib in ongoing trials, including phase I and II studies of combination regimens, and the randomized phase III trials ASPIRE, FOCUS, ENDEAVOR, and CLARION. Additional studies are underway to examine alternative dosing schedules (e.g., once-weekly dosing [CHAMPION-1]).
    MeSH term(s) Animals ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/therapeutic use ; Clinical Trials as Topic ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug Approval ; Humans ; Infusions, Intravenous ; Multiple Myeloma/drug therapy ; Multiple Myeloma/pathology ; Multiple Myeloma/prevention & control ; Oligopeptides/administration & dosage ; Oligopeptides/therapeutic use ; Proteasome Inhibitors/administration & dosage ; Proteasome Inhibitors/therapeutic use ; United States
    Chemical Substances Antineoplastic Agents ; Oligopeptides ; Proteasome Inhibitors ; carfilzomib (72X6E3J5AR)
    Language English
    Publishing date 2014-07
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 125102-8
    ISSN 1532-1967 ; 0305-7372
    ISSN (online) 1532-1967
    ISSN 0305-7372
    DOI 10.1016/j.ctrv.2014.02.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1022: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 611: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top